Elevated Expression Levels of Inhibitory Receptor Programmed Death 1 on Simian Immunodeficiency Virus-specific CD8 T Cells During Chronic Infection but Not After Vaccination
Overview
Authors
Affiliations
Here, we study the temporal expression of the inhibitory receptor programmed death 1 (PD-1) on simian immunodeficiency virus (SIV) Gag-specific T cells following pathogenic SIV infection or following vaccination with a DNA/modified vaccinia virus Ankara (DNA/MVA) vaccine and simian/human immunodeficiency virus (SHIV) challenge in macaques. Following infection, the majority (>95%) of Gag-specific CD8 T cells expressed PD-1, and the level of PD-1 expression per cell increased over time. The level of PD-1 expression in lymph nodes and rectal mucosal tissue, the major sites of virus replication, was higher compared to blood. In vitro blockade of PD-1 resulted in enhanced proliferation of SIV-specific CD8 as well as CD4 T cells. In contrast, following vaccination, the majority of peak effector Gag-specific CD8 T cells expressed low levels of PD-1, and these levels decreased further as the cells differentiated into memory cells. In addition, following SHIV challenge of these vaccinated macaques, the level of PD-1 expression on Gag-specific CD8 T cells correlated positively with plasma viremia. These results demonstrate that SIV-specific CD8 T cells express PD-1 after exposure to antigen but downregulate expression under conditions of antigen clearance and enhance expression under conditions of antigen persistence. They also demonstrate that the level of PD-1 expression per cell rather than the presence or absence of expression plays an important role in regulating CD8 T-cell dysfunction in pathogenic SIV infection. In addition, they demonstrate that similar to HIV infection, the PD-1:PD-1 ligand inhibitory pathway is operational in pathogenic SIV infection, and the macaque/SIV model would be ideal to test the safety and therapeutic benefit of blocking this pathway in vivo.
Immune checkpoint inhibitors in infectious disease.
King H, Lewin S Immunol Rev. 2024; 328(1):350-371.
PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.
Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.
Webb G, Pessoa C, McCullen A, Hwang J, Humkey M, Thormin-Odum R J Virol. 2024; 98(6):e0027324.
PMID: 38775481 PMC: 11237531. DOI: 10.1128/jvi.00273-24.
Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.
Mu W, Patankar V, Kitchen S, Zhen A Viruses. 2024; 16(2).
PMID: 38399994 PMC: 10893210. DOI: 10.3390/v16020219.
Kleinman A, Sivanandham S, Sette P, Sivanandham R, Policicchio B, Xu C J Virol. 2022; 96(12):e0044522.
PMID: 35638831 PMC: 9215247. DOI: 10.1128/jvi.00445-22.
Lymph node CXCR5+ NK cells associate with control of chronic SHIV infection.
Rahman S, Billingsley J, Sharma A, Styles T, Govindaraj S, Shanmugasundaram U JCI Insight. 2022; 7(8).
PMID: 35271506 PMC: 9089783. DOI: 10.1172/jci.insight.155601.